Komori
KYORIN Pharmaceutical (4569) · RiskRestated

Litigation Concerning Patents, Product Liability and Antitrust Law

First written in FY2017. 2 of 3 entries say "Restated". Latest entry: FY2019.

3entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – FY20192017: 120172018: 120182019: 12019
Same theme, other companies
Risk of Litigation and Business Restrictions Across Multiple Areas, Including Regulatory Violations, Intellectual Property and Product LiabilityA theme 37 companies write about · 37 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2024: 4 of 8 companies on the "Worse" side.

22 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 37 companies compared. The sentences above are computed from all 37.
Full recordFilings, disclosures and news, newest first
  1. FY2019RestatedAnnual report

    「The Group may face lawsuits concerning patents, product liability under the PL Act, antitrust law, environmental protection, labor matters and other issues arising in its business activities.」

    The company continues to disclose litigation risks relating to patents, the Product Liability Act, the Antimonopoly Act, environmental matters, labor matters and other issues.
  2. FY2018RestatedAnnual report

    「The Group may face lawsuits concerning patents, product liability under the PL Act, antitrust law, environmental protection, labor matters and other issues arising in its business activities.」

    The company continues to disclose litigation risks relating to patents, the Product Liability Act, the Antimonopoly Act, environmental matters, labor matters and other issues.
  3. FY2017First statedAnnual report

    「The Group may face lawsuits concerning patents, product liability under the PL Act, antitrust law, environmental protection, labor matters and other issues arising in its business activities.」

    The Group discloses general litigation risks concerning patents, product liability, antitrust law, environmental matters and labor matters.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.